On 1st November, 2017, Mr. Zhang Boqing, the chairman of Beroni Group was invited to attend the Industry Cooperation Round Table Conference held by UNSW Torch Innovation Park in Beijing Torch High-tech Industry Development Center. In the meantime, Mr. Zhang Boqing, the chairman of Beroni Group and Ian Jacobs, the principal of University of New South Wales made a deeply communication in the field of technological innovation and then signed a strategic cooperation agreement. That means that Beroni Group will invest and support the Phase II clinical study of brain anti-neoplastic drugs at the University of New South Wales.
This is a a great advance for Beroni Group after listing on National Stock Exchange of Australia. Beroni Group has been deeply involved in Australia in the field of biotechnology and life sciences and has made a substantial progress.
Since the initiative of “Belt and Road ” has been put forward, the relations between China and Australia is steady. The two countries have been actively expanding the cooperation in the fields of resources, infrastructures and scientific and technological innovation. University of New South Wales actively joins the Torch Program, which is one of the international cooperation projects between China and Australia. Its aim is promoting the development of scientific and technological industry in China and Australia.
The chairman of Beroni Group, Mr. Zhang Boqing said, it was his honour to attend to this round-table conference and witness the technological achievements in 2017. The University of New South Wales is a leading research-intensive university in the Asia Pacific region. It has a strong competitiveness in technological studies and has achieved remarkable results in biological medicine and life sciences. Scientific and technological innovation is the core idea both of Beroni Group and the University of New South Wales. Beroni Group hopes that through the cooperation to work together for the development of biotechnology innovation in China and Australia.
During the conference, Beroni Group signed a strategic cooperation agreement with University of New South Wales successfully. Beroni Group plans to invest the Phase II clinical study of brain anti-neoplastic drugs to promote the project of biomedical research and development. Mr. Zhang Boqing said, technological innovation is the core objective of two parties. He expected that they can contribute to human health together by transforming science and technology into products.
At last, the representatives of both parties took a group photo. Up to now, the globalization of Beroni Group is developing steadily. In the future, Beroni Group will integrate and take advantage of global scientific and technological resources to promote the transformation of scientific and technological achievements and benefit the career of human health.